Live Analyst Rating Changes 23245 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Patrick B Donnelly
Citi

Patrick B Donnelly

Wall Street Analyst
★★★★★
#69
on 13Foresight · ranked by our own returns
78%
Success Rate
+17.3%
Average Return
42 of 54 calls profitable · +9.0% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 78% of Patrick B Donnelly's ratings turned a profit when each position was held for 1 year — averaging +17.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

73 Buy 47 Hold 5 Sell
Patrick's Stock Coverage 34 ratings · 2026-08-12
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
QGEN
Qiagen
Aug 10, 2026 HOLD Buy
+0.3% avg upside
24 analysts
$45.00
5.43% Upside
· ·
SHC
Sotera Health
Aug 07, 2026 BUY Strong Buy
+15.6% avg upside
13 analysts
$25.00
30.83% Upside
+0.2% ·
TXG
10x Genomics
Aug 07, 2026 HOLD Buy
-29.5% avg upside
18 analysts
$50.00
14.56% Downside
+15.7% ·
NTRA
Natera
Aug 07, 2026 BUY Strong Buy
-5.7% avg upside
27 analysts
$315.00
0.77% Upside
-2.0% ·
BRKR
Bruker
Aug 05, 2026 HOLD Buy
+0.3% avg upside
22 analysts
$53.00
7.07% Downside
+9.2% ·
ILMN
Illumina
Aug 03, 2026 SELL Buy
-8.8% avg upside
31 analysts
$113.00
41.48% Downside
+3.5% ·
FTRE
Fortrea Holdings Inc.
Jul 31, 2026 BUY Buy
+8.0% avg upside
12 analysts
$22.00
12.69% Upside
-0.9% ·
DHR
Danaher
Jul 22, 2026 BUY Strong Buy
+1.6% avg upside
45 analysts
$230.00
10.90% Upside
+14.3% ·
MTD
Mettler-Toledo
Jul 08, 2026 BUY Buy
-15.4% avg upside
18 analysts
$1550.00
7.85% Upside
+15.1% ·
STVN
Stevanato Group
Jul 08, 2026 BUY Strong Buy
+31.2% avg upside
13 analysts
$26.00
23.48% Upside
+7.1% ·
AVTR
Avantor
Jul 08, 2026 HOLD Buy
+12.6% avg upside
26 analysts
$11.00
20.14% Downside
+42.7% ·
GH
Guardant Health
Jul 08, 2026 BUY Strong Buy
-1.1% avg upside
31 analysts
$215.00
30.32% Upside
+4.9% ·
QDEL
QuidelOrtho
Jul 08, 2026 HOLD Buy
+183.5% avg upside
13 analysts
$18.00
28.62% Upside
-20.2% ·
CRL
Charles River Labs
Jul 08, 2026 BUY Strong Buy
-16.3% avg upside
35 analysts
$265.00
6.01% Downside
+25.9% ·
TECH
Bio-Techne
Jun 29, 2026 HOLD Buy
+15.6% avg upside
21 analysts
$73.00
1.14% Upside
+2.0% ·
ICLR
Icon
Jun 25, 2026 HOLD Strong Buy
+13.8% avg upside
26 analysts
$165.00
0.33% Downside
+1.6% ·
CAI
Caris Life Sciences, Inc.
May 08, 2026 BUY Strong Buy
+19.9% avg upside
20 analysts
$28.00
21.02% Upside
+37.9% ·
MDLN
Medline
May 06, 2026 BUY Strong Buy
+35.6% avg upside
27 analysts
$55.00
56.90% Upside
-19.5% ·
WST
West Pharmaceutical Services
Apr 24, 2026 BUY Strong Buy
+4.4% avg upside
18 analysts
$400.00
13.91% Upside
+14.9% ·
IQV
IQVIA Holdings
Apr 07, 2026 HOLD Strong Buy
-0.4% avg upside
39 analysts
$200.00
17.91% Downside
+41.7% ·
WAT
Waters
Apr 07, 2026 BUY Strong Buy
-5.0% avg upside
31 analysts
$425.00
2.35% Upside
+32.4% ·
BIO
Bio-Rad Laboratories
Apr 07, 2026 HOLD Buy
+1.0% avg upside
9 analysts
$300.00
15.76% Downside
+27.5% ·
TMO
Thermo Fisher
Apr 06, 2026 BUY Strong Buy
+0.2% avg upside
38 analysts
$685.00
13.20% Upside
+23.0% ·
A
Agilent
Mar 11, 2026 BUY Strong Buy
-0.2% avg upside
33 analysts
$185.00
23.77% Upside
+29.5% ·
DGX
Quest Diagnostics
Feb 11, 2026 HOLD Buy
-22.7% avg upside
34 analysts
$215.00
9.43% Downside
+14.8% ·
LH
Labcorp Holdings
Jan 02, 2026 BUY Strong Buy
-15.8% avg upside
37 analysts
$325.00
0.88% Upside
+28.3% ·
RVTY
Revvity
May 22, 2025 BUY Buy
-6.4% avg upside
23 analysts
$135.00
16.66% Upside
+7.5% ·
OSUR
Orasure Technologies
Feb 26, 2025 BUY Buy
+118.0% avg upside
11 analysts
$6.00
54.71% Upside
+0.7% ·
SERA
Sera Prognostics
Mar 23, 2023 HOLD Strong Buy
+271.4% avg upside
7 analysts
$4.25
113.54% Upside
+163.8% ·
BEAM
Beam Therapeutics
Mar 01, 2023 BUY Strong Buy
+93.4% avg upside
25 analysts
$62.00
130.98% Upside
+3.5% ·
PSNL
Personalis
Feb 24, 2023 BUY Strong Buy
+2.7% avg upside
11 analysts
$6.00
57.22% Downside
-56.6% ·
ADPT
Adaptive Biotechnologies
Aug 14, 2019 HOLD Strong Buy
-6.4% avg upside
15 analysts
$36.00
41.81% Upside
-9.6% ·
TTOO
T2 Biosystems
Nov 30, 2018 HOLD Buy
+1421150.0% avg upside
10 analysts
$4.50
899899.96% Upside
· ·
MYGN
Myriad Genetics
Nov 30, 2018 HOLD Hold
+455.0% avg upside
24 analysts
$32.00
893.75% Upside
-20.2% ·
🔒 29 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Patrick B Donnelly — Frequently Asked Questions
How accurate are Patrick B Donnelly's stock ratings?
Based on the calls 13Foresight could measure, about 78% of Patrick's ratings were profitable over a one-year hold, with an average return of +17.4% per rating, or +9.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Patrick ranked on 13Foresight?
Patrick B Donnelly is currently ranked #69 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Patrick cover?
Patrick most recently has ratings on QGEN, SHC, TXG, NTRA, BRKR, ILMN, FTRE, DHR, MTD, STVN, AVTR, GH and 22 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.